Restricting CAR T Cell Trafficking Expands Targetable Antigen Space

Erin A. Morales,Kenneth A. Dietze,Jillian M. Baker,Alexander Wang,Stephanie V. Avila,Fiorella Iglesias,Sabarinath V. Radhakrishnan,Erica Vander Mause,Michael L. Olson,Wenxiang Sun,Ethan Rosati,Sadie L. Chidester,Thierry Iraguha,Xiaoxuan Fan,Djordje Atanackovic,Tim Luetkens
DOI: https://doi.org/10.1101/2024.02.08.579002
2024-02-11
Abstract:Chimeric antigen receptor (CAR) T cells are an effective treatment for some blood cancers. However, the lack of tumor-specific surface antigens limits their wider use. We identified a set of surface antigens that are limited in their expression to cancer and the central nervous system (CNS). We developed CAR T cells against one of these antigens, LINGO1, which is widely expressed in Ewing sarcoma (ES). To prevent CNS targeting, we engineered LINGO1 CAR T cells lacking integrin ⍺ (A4 ), an adhesion molecule essential for migration across the blood-brain barrier. A4 LINGO1 CAR T cells were efficiently excluded from the CNS but retained efficacy against ES. We show that altering adhesion behavior expands the set of surface antigens targetable by CAR T cells.
Bioengineering
What problem does this paper attempt to address?
This paper discusses how to expand the targetable antigen range in CAR (chimeric antigen receptor) T cell therapy by restricting the migration of CAR T cells, thus addressing the limitations of CAR T cell therapy in cancer treatment. Researchers discovered a group of surface antigens specifically expressed in cancer and the central nervous system (CNS), and selected one called LINGO1 to develop CAR T cells. To prevent CNS toxicity, they designed LINGO1 CAR T cells lacking integrin alpha-4 (A4ko) that are unable to cross the blood-brain barrier but still retain cytotoxic activity against Ewing sarcoma (ES). By modifying T cell adhesion behavior, the researchers demonstrated how to provide tissue selectivity for CAR T cell therapy, reducing side effects on normal tissues and expanding the targetable antigen pool. Experimental results showed that A4ko LINGO1 CAR T cells effectively eliminated ES both in vitro and in vivo without adverse effects on the CNS. This work provides a new strategy to improve the safety and expand the application scope of CAR T cell therapy.